Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 8/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 8/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 8/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6104735 | 0.91 | HTR6 (0.44) | CA2HTR6ADRA1DADRA1AADRA1B | |
| SCHEMBL14364266 | 0.84 | CA2 (0.39) | CA2ADRA1DADRA1AADRA1BCYP2D6 | |
| SCHEMBL4961952 | 0.84 | CA2 (0.39) | CA2ADRA1DADRA1AADRA1BCYP2D6 | |
| SCHEMBL4961732 | 0.84 | HTR6 (0.41) | CA2HTR6ADRA1DADRA1AADRA1B | |
| SCHEMBL4962088 | 0.83 | CA2 (0.53) | CA2HTR6ADRA1DADRA1AADRA1B | |
| SCHEMBL4961831 | 0.83 | ADRA1D (0.47) | CA2HTR6ADRA1DADRA1AADRA1B | |
| SCHEMBL4958748 | 0.82 | CA2 (0.52) | CA2HTR6ADRA1DADRA1AADRA1B | |
| SCHEMBL4965335 | 0.82 | ADRA1D (0.47) | CA2HTR6ADRA1DADRA1AADRA1B | |
| SCHEMBL4961050 | 0.82 | CA2 (0.38) | CA2ADRA1DADRA1AADRA1BCYP2D6 | |
| SCHEMBL4964294 | 0.81 | ADRA1D (0.54) | ADRA1DADRA1AADRA1BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871759-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006116158-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | CA2 4153/4885HTR6 117/4885ADRA1D 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.